<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND OBJECTIVES: The two main complications of severe <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0001875'>neutropenia</z:hpo> are fatal <z:hpo ids='HP_0100806'>sepsis</z:hpo> and <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo>/<z:hpo ids='HP_0002488'>acute leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/AL) </plain></SENT>
<SENT sid="1" pm="."><plain>Granulocyte colony-stimulating factor (G-CSF) therapy has significantly reduced the frequency and severity of <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e>, but its possible influence on the risk of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> is not known </plain></SENT>
<SENT sid="2" pm="."><plain>DESIGN AND METHODS: The French Severe <z:hpo ids='HP_0011010'>Chronic</z:hpo> <z:hpo ids='HP_0001875'>Neutropenia</z:hpo> <z:chebi fb="0" ids="29425">(SCN)</z:chebi> Registry has prospectively collected data since 1994 on 231 patients with various forms of <z:chebi fb="0" ids="18022">SCN</z:chebi>, namely severe <z:hpo ids='HP_0005549'>congenital neutropenia</z:hpo> (n=101), cyclic <z:hpo ids='HP_0001875'>neutropenia</z:hpo> (n=60), <z:chebi fb="15" ids="28087">glycogen</z:chebi> <z:e sem="disease" ids="C0267971" disease_type="Disease or Syndrome" abbrv="">storage disease</z:e> type Ib (GSDIb) (n=15) and <z:e sem="disease" ids="C0272170" disease_type="Disease or Syndrome" abbrv="">Shwachman-Diamond syndrome</z:e> (<z:chebi fb="26" ids="8984">SDS</z:chebi>)(n=55) </plain></SENT>
<SENT sid="3" pm="."><plain>The median overall follow-up is 11.1 years </plain></SENT>
<SENT sid="4" pm="."><plain>Parameters of exposure to G-CSF therapy, such as the time averaged dose, follow up after first use of G-CSF, and the cumulative dose, have been recorded </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Eight septic <z:hpo ids='HP_0011420'>deaths</z:hpo> occurred, of which 6 among patients with severe <z:hpo ids='HP_0005549'>congenital neutropenia</z:hpo> and 2 in patients with cyclic <z:hpo ids='HP_0001875'>neutropenia</z:hpo>; none of these 8 patients was receiving G-CSF therapy </plain></SENT>
<SENT sid="6" pm="."><plain>No septic <z:hpo ids='HP_0011420'>deaths</z:hpo> occurred during G-CSF therapy </plain></SENT>
<SENT sid="7" pm="."><plain>Thirteen cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/AL were recorded </plain></SENT>
<SENT sid="8" pm="."><plain>The cumulative incidence of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/AL was 2.7% (SD 1.3%) at 10 years and 8.1% (SD 2.7%) at 20 years </plain></SENT>
<SENT sid="9" pm="."><plain>INTERPRETATION AND CONCLUSIONS: Risk factors for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/AL were the diagnostic category, the severity of <z:hpo ids='HP_0001875'>neutropenia</z:hpo>, younger age at diagnosis, and strong exposure to G-CSF </plain></SENT>
<SENT sid="10" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/AL only occurred in patients with severe <z:hpo ids='HP_0005549'>congenital neutropenia</z:hpo> and <z:chebi fb="26" ids="8984">SDS</z:chebi> </plain></SENT>
<SENT sid="11" pm="."><plain>Owing to their particular <z:hpo ids='HP_0002719'>susceptibility to infections</z:hpo>, patients with severe <z:hpo ids='HP_0005549'>congenital neutropenia</z:hpo> had the strongest exposure to G-CSF; the risk of <z:hpo ids='HP_0001909'>leukemia</z:hpo> increased with the degree of G-CSF exposure in this subgroup </plain></SENT>
</text></document>